These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 17994125)

  • 21. Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation.
    Gurkan E; Patah PA; Saliba RM; Ramos CA; Anderson BS; Champlin R; de Lima M; Lichtiger B
    Bone Marrow Transplant; 2007 Sep; 40(5):461-4. PubMed ID: 17589530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Skin cancer after nonmyeloablative hematopoietic cell transplantation.
    Cavalier M; Shmalo JA; Yu M; Billings SD; Abonour R; Nelson RP
    Bone Marrow Transplant; 2006 Jun; 37(12):1103-8. PubMed ID: 16757973
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overcoming various comorbidities by G-CSF-primed unmanipulated BM SCT in adult patients with AML.
    Kim HJ; Min WS; Cho BS; Eom KS; Kim SY; Kim YJ; Lee S; Min CK; Cho SG; Lee JW; Kim CC
    Bone Marrow Transplant; 2009 Sep; 44(6):345-51. PubMed ID: 19270728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies.
    Díez-Campelo M; Pérez-Simón JA; Pérez J; Alcoceba M; Richtmon J; Vidriales B; San Miguel J
    Am J Hematol; 2009 Mar; 84(3):149-52. PubMed ID: 19123459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transplant strategies for myelodysplastic syndrome.
    McCarty J
    Best Pract Res Clin Haematol; 2004 Dec; 17(4):559-72. PubMed ID: 15494294
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allogeneic stem cell transplantation for myelodysplastic syndrome.
    Barrett AJ; Savani BN
    Semin Hematol; 2008 Jan; 45(1):49-59. PubMed ID: 18179969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission.
    Schmid C; Schleuning M; Hentrich M; Markl GE; Gerbitz A; Tischer J; Ledderose G; Oruzio D; Hiddemann W; Kolb HJ
    Bone Marrow Transplant; 2008 Apr; 41(8):721-7. PubMed ID: 18176613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stem cell transplantation in patients with severe congenital neutropenia with evidence of leukemic transformation.
    Choi SW; Boxer LA; Pulsipher MA; Roulston D; Hutchinson RJ; Yanik GA; Cooke KR; Ferrara JL; Levine JE
    Bone Marrow Transplant; 2005 Mar; 35(5):473-7. PubMed ID: 15640815
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Haematopoietic cell transplantation with non-myeloablative conditioning in Denmark: disease-specific outcome, complications and hospitalization requirements of the first 100 transplants.
    Kornblit B; Masmas T; Madsen HO; Ryder LP; Svejgaard A; Jakobsen B; Sengeløv H; Olesen G; Heilmann C; Dickmeiss E; Petersen SL; Vindeløv L
    Bone Marrow Transplant; 2008 May; 41(10):851-9. PubMed ID: 18246114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allogeneic stem cell transplantation for myelodysplastic syndromes in children: a report from the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON).
    Muñoz A; Díaz-Heredia C; Badell I; Bureo E; Gómez P; Martínez A; Verdeguer A; Pérez-Hurtado JM; Fernández-Delgado R; González-Vicent M; Maldonado MS
    Pediatr Hematol Oncol; 2009; 26(5):345-55. PubMed ID: 19579081
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia.
    Ringdén O; Labopin M; Ehninger G; Niederwieser D; Olsson R; Basara N; Finke J; Schwerdtfeger R; Eder M; Bunjes D; Gorin NC; Mohty M; Rocha V
    J Clin Oncol; 2009 Sep; 27(27):4570-7. PubMed ID: 19652066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bone marrow transplant in myelodysplastic syndromes: new technologies, same questions.
    Giralt S
    Curr Hematol Rep; 2005 May; 4(3):200-7. PubMed ID: 15865872
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).
    Patriarca F; Bacigalupo A; Sperotto A; Isola M; Soldano F; Bruno B; van Lint MT; Iori AP; Santarone S; Porretto F; Pioltelli P; Visani G; Iacopino P; Fanin R; Bosi A;
    Haematologica; 2008 Oct; 93(10):1514-22. PubMed ID: 18728030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in stem cell transplantation: making it better and safer.
    Giralt S
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S293-5. PubMed ID: 19778855
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum ferritin and disease status at transplantation predict the outcome of allo-SCT in patients with AML or myelodysplastic syndrome.
    Tachibana T; Takasaki H; Tanaka M; Maruta A; Hyo R; Ishigatsubo Y; Kanamori H
    Bone Marrow Transplant; 2011 Jan; 46(1):150-1. PubMed ID: 20383206
    [No Abstract]   [Full Text] [Related]  

  • 36. Characterization of hemopoietic engraftment kinetics and development of secondary cytopenia in AML post auto-SCT and its correlation with survival outcome.
    Babatunde AS; Tan DC; Heng KK; Lee JJ; Loh YS; Hwang WY; Koh MB; Goh YT; Linn YC
    Bone Marrow Transplant; 2009 Aug; 44(3):175-83. PubMed ID: 19204715
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.
    Lekakis L; de Lima M
    Expert Rev Anticancer Ther; 2008 May; 8(5):785-98. PubMed ID: 18471050
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcome after reduced-intensity conditioning allogeneic SCT for AML in first complete remission: comparison of two regimens.
    Cahu X; Mohty M; Faucher C; Chevalier P; Vey N; El-Cheikh J; Guillaume T; Furst S; Delaunay J; Ayari S; Moreau P; Gastaut JA; Harousseau JL; Blaise D
    Bone Marrow Transplant; 2008 Nov; 42(10):689-91. PubMed ID: 18679370
    [No Abstract]   [Full Text] [Related]  

  • 39. Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group.
    Schetelig J; Bornhäuser M; Schmid C; Hertenstein B; Schwerdtfeger R; Martin H; Stelljes M; Hegenbart U; Schäfer-Eckart K; Füssel M; Wiedemann B; Thiede C; Kienast J; Baurmann H; Ganser A; Kolb HJ; Ehninger G
    J Clin Oncol; 2008 Nov; 26(32):5183-91. PubMed ID: 18768435
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Leukemia in donor cells after allogeneic hematopoietic stem cell transplant.
    Brunstein CG; Hirsch BA; Hammerschmidt D; McGlennen RC; Nguyen PL; Verfaillie CM
    Bone Marrow Transplant; 2002 Jun; 29(12):999-1003. PubMed ID: 12098070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.